Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Oncol Rep ; 37(3): 1889-1895, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28098874

ABSTRACT

Natural killer (NK) cells have the potential to be effective killers of tumor cells. They are governed by inhibitory and activating receptors such as NKG2D, whose ligands are normally upregulated in cells that are stressed, like cancer cells. Advanced cancer cells, however, have ways to reduce the expression of these ligands, leaving them less detectable by NK cells. Along with these receptors, NK cells also require activating cytokines, such as IL-12. A previous study in our laboratory showed that a fusion protein of the extracellular domain of mouse UL-16 binding protein-like transcript 1 (MULT1E) and mouse interleukin 12 (IL-12) can effectively activate mouse NK cells by in vitro assays and in vivo in animal tumor models. The aim of the present study was to expand the concept of developing a novel bifunctional fusion protein for enhanced NK cell activation to human killer cells. The proposed protein combines the extracellular domain of a human NKG2D ligand, MHC class I polypeptide-related sequence A (MICA) and IL-12. It is hypothesized that when expressed by tumor cells, the protein will activate human NK and other killer cells using the NKG2D receptor, and deliver IL-12 to the NK cells where it can interact with the IL-12R and enhance cytotoxicity. The fusion protein, when expressed by engineered tumor cells, indeed activated NK92 cells as measured by an increase in interferon-γ (IFN-γ) production and an increase in cytotoxicity of tumor cells. The fusion protein was also able to increase the proliferation of human peripheral blood mononuclear cells (PBMCs) and augment their production of IFN-γ. This study along with the data from the previous mouse studies suggest that the MICA/IL-12 bifunctional fusion protein represents an effective activator of killer cells for cancer treatment.


Subject(s)
Histocompatibility Antigens Class I/metabolism , Interleukin-12/metabolism , Killer Cells, Natural/immunology , Lung Neoplasms/immunology , Lymphocyte Activation/immunology , Animals , Apoptosis , Cell Proliferation , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation, Neoplastic , Histocompatibility Antigens Class I/genetics , Humans , Interleukin-12/genetics , Killer Cells, Natural/metabolism , Killer Cells, Natural/pathology , Leukocytes, Mononuclear/immunology , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice , NK Cell Lectin-Like Receptor Subfamily K/genetics , NK Cell Lectin-Like Receptor Subfamily K/metabolism , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
2.
Int J Oncol ; 48(6): 2381-6, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27081758

ABSTRACT

Whereas cancer immunotherapy with cytokines in recent research was demonstrated effective in activating immune response against tumor cells, one major obstacle with the use of these cytokines is their severe side effects when delivered systemically at high doses. Another challenge is that advanced tumor cells often evade immunosurveillance of the immune system as well as of the Fas-mediated apoptosis by various mechanisms. We report the design and preliminary evaluation of the antitumor activity of a novel fusion protein-mIL-12/FasTI, consisting of mouse interleukin-12 and the transmembrane and intracellular domains of mouse Fas. The fusion construct (pmIL-12/FasTI) was transfected into mouse lung carcinoma cell line TC-1. Stable cell clones expressing the fusion protein were established as assayed by RT-PCR and immunohistochemistry. ELISA and cell proliferation analyses demonstrated that NK cells were effectively activated by the fusion protein with increased IFN-γ production and cytotoxicity. Enhanced caspase-3 activity of the clones when co-cultured with NK cells indicated that apoptosis was induced through Fas/FasL signaling pathway. The preliminary results suggest a synergized anticancer activity of the fusion protein. It may represent a promising therapeutic agent for cancer treatment.


Subject(s)
Genetic Therapy/methods , Immunotherapy/methods , Interleukin-12/biosynthesis , Lung Neoplasms/therapy , Recombinant Fusion Proteins/biosynthesis , fas Receptor/biosynthesis , Animals , Cell Line, Tumor , DNA, Complementary/genetics , Humans , Interleukin-12/genetics , Interleukin-12/immunology , Killer Cells, Natural/immunology , Lung Neoplasms/genetics , Lung Neoplasms/immunology , Lymphocyte Activation , Mice , Plasmids/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Transfection , fas Receptor/genetics , fas Receptor/immunology
3.
Biomater Sci ; 4(4): 614-26, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26845086

ABSTRACT

Survivin belongs to the family of inhibitor of apoptosis proteins (IAP) and is present in most cancers while being below detection limits in most terminally differentiated adult tissues, making it an attractive protein to target for diagnostic and, potentially, therapeutic roles. Sub-100 nm poly(propargyl acrylate) (PA) particles were surface modified through the copper-catalyzed azide/alkyne cycloaddition of an azide-terminated survivin ligand derivative (azTM) originally proposed by Abbott Laboratories and speculated to bind directly to survivin (protein) at its dimer interface. Using affinity pull-down studies, it was determined that the PA/azTM nanoparticles selectively bind survivin and the particles can enhance apoptotic cell death in glioblastoma cell lines and other survivin over-expressing cell lines such as A549 and MCF7 relative to cells incubated with the original Abbott-derived small molecule inhibitor.


Subject(s)
Acrylates/chemistry , Apoptosis , Azides/chemistry , Inhibitor of Apoptosis Proteins/chemistry , Nanoparticles/chemistry , Neoplasm Proteins/chemistry , Polymers/chemistry , Apoptosis/physiology , Azides/pharmacology , Catalysis , Cell Line, Tumor , Copper/chemistry , Cycloaddition Reaction , Humans , Inhibitor of Apoptosis Proteins/metabolism , Inhibitor of Apoptosis Proteins/pharmacology , Ligands , Microtubule-Associated Proteins/chemistry , Microtubule-Associated Proteins/metabolism , Neoplasm Proteins/metabolism
4.
PLoS One ; 9(11): e113116, 2014.
Article in English | MEDLINE | ID: mdl-25420022

ABSTRACT

Brain development requires precise orchestration of cellular events through the coordinate exchange of information between distally located cells. One mechanism by which intercellular communication is achieved is through the transfer of extracellular vesicles (EVs). Exosomes are EVs that carry lipids, nucleic acids, and proteins and are detectable in most biological fluids including cerebrospinal fluid (CSF). Here we report that CSF EV concentrations undergo age dependent fluctuations. We characterized EV RNA content by next generation small RNA sequencing and miRNA microarray analysis and identified a temporal shift in CSF EV content. CSF EVs encapsulated miRNAs that contain a conserved hnRNPA2/B1 recognition sequence. We found that hnRNPA2/B1-containing EVs were produced by choroid plexus epithelial cells and that hnRNPA2/B1 containing EVs decreased with age. These results provide insight into EV exchange of miRNAs within the central nervous system and a framework to understand how changes in EVs may have an important impact on brain development.


Subject(s)
Cell-Derived Microparticles/genetics , Exosomes/genetics , MicroRNAs/genetics , RNA, Untranslated/genetics , Adolescent , Age Factors , Aged , Aged, 80 and over , Base Sequence , Cell-Derived Microparticles/metabolism , Cell-Derived Microparticles/ultrastructure , Cerebrospinal Fluid/metabolism , Child , Choroid Plexus/cytology , Choroid Plexus/metabolism , Epithelial Cells/metabolism , Exosomes/metabolism , Exosomes/ultrastructure , Heterogeneous-Nuclear Ribonucleoprotein Group A-B/metabolism , High-Throughput Nucleotide Sequencing , Humans , Immunoblotting , Infant , Infant, Newborn , MicroRNAs/metabolism , Microscopy, Electron, Transmission , Oligonucleotide Array Sequence Analysis , RNA, Untranslated/cerebrospinal fluid , Sequence Homology, Nucleic Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...